The efficacy of cyclophosphamide in the treatment of Kawasaki disease complicated with coronary artery aneurysms in children: insights from a single-center experience

Objective Giant coronary artery aneurysms (g-CAA) are the most dangerous complications for children with Kawasaki disease (KD). Before 2025, once the fever subsides, there are no treatment recommendations for preventing the progression of CAA. This study aims to evaluate CAA outcomes over 2 years in children with KD complicated by CAA treated with intravenous and/or oral cyclophosphamide (CTX), compared with conventional therapy alone. Methods A total of 41 children with KD along with at least one CAA ≥4 mm or Z score ≥5 were enrolled. All patients were diagnosed and treated at the Department of Pediatric Cardiology, Shengjing Hospital Affiliated to China Medical University, between March 2012 and September 2026, with a follow-up duration of at least 2 years. 21 patients receiving conventional therapy served as the control group (Ctrl). From February 2021 onward, 20 children with midgrade or giant CAA received additional CTX therapy and were assigned to the CTX group (CTX-G). CTX treatment included a single intravenous dose (2 mg/kg) and/or oral CTX initiated within 4 months of disease onset (1.5 mg/kg/day for 3 months, followed by a 2-month break as one treatment cycle). The mean initiation time for oral CTX was 2.4 months after disease onset, with an average treatment duration of 4.4 months. Results Improvement was observed in 2 infants with CAA ≥8 mm in RCA, with diameters decreasing from 8.5 mm (Z = 20.71) and 9.1 mm (Z = 20.08) to 6.3 mm (Z = 10.4) and 4.4 mm (Z = 5.67), respectively. In patients with CAA ≥4 mm and <8 mm with Z ≥10, baseline coronary dimensions and Z scores of the LAD and RCA did not differ between groups (P > 0.05). After 2 years, both the inner diameter and Z score of the RCA in CTX-G were significantly smaller than those in Ctrl (P < 0.05). Conclusion CAA ≥8 mm involving the RCA in young patients may demonstrate partial regression. For patients with CAA ≥4 mm and <8 mm with Z ≥10, early CTX treatment may effectively limit further aneurysm progression, particularly in the RCA.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-18
DOI
https://doi.org/10.3389/fimmu.2026.1813681
Primary Topic
Kawasaki Disease and Coronary Complications
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The efficacy of cyclophosphamide in the treatment of Kawasaki disease complicated with coronary artery aneurysms in children: insights from a single-center experience

Jinghao Li, Hong Wang, Yunming Xu, Yangqiu Chu
1 links
Frontiers in Immunology
Kawasaki Disease and Coronary Complications
article

The efficacy of cyclophosphamide in the treatment of Kawasaki disease complicated with coronary artery aneurysms in children: insights from a single-center experience

Jinghao Li, Hong Wang, Yunming Xu, Yangqiu Chu
article en

Abstract

Objective Giant coronary artery aneurysms (g-CAA) are the most dangerous complications for children with Kawasaki disease (KD). Before 2025, once the fever subsides, there are no treatment recommendations for preventing the progression of CAA. This study aims to evaluate CAA outcomes over 2 years in children with KD complicated by CAA treated with intravenous and/or oral cyclophosphamide (CTX), compared with conventional therapy alone. Methods A total of 41 children with KD along with at least one CAA ≥4 mm or Z score ≥5 were enrolled. All patients were diagnosed and treated at the Department of Pediatric Cardiology, Shengjing Hospital Affiliated to China Medical University, between March 2012 and September 2026, with a follow-up duration of at least 2 years. 21 patients receiving conventional therapy served as the control group (Ctrl). From February 2021 onward, 20 children with midgrade or giant CAA received additional CTX therapy and were assigned to the CTX group (CTX-G). CTX treatment included a single intravenous dose (2 mg/kg) and/or oral CTX initiated within 4 months of disease onset (1.5 mg/kg/day for 3 months, followed by a 2-month break as one treatment cycle). The mean initiation time for oral CTX was 2.4 months after disease onset, with an average treatment duration of 4.4 months. Results Improvement was observed in 2 infants with CAA ≥8 mm in RCA, with diameters decreasing from 8.5 mm (Z = 20.71) and 9.1 mm (Z = 20.08) to 6.3 mm (Z = 10.4) and 4.4 mm (Z = 5.67), respectively. In patients with CAA ≥4 mm and <8 mm with Z ≥10, baseline coronary dimensions and Z scores of the LAD and RCA did not differ between groups (P > 0.05). After 2 years, both the inner diameter and Z score of the RCA in CTX-G were significantly smaller than those in Ctrl (P < 0.05). Conclusion CAA ≥8 mm involving the RCA in young patients may demonstrate partial regression. For patients with CAA ≥4 mm and <8 mm with Z ≥10, early CTX treatment may effectively limit further aneurysm progression, particularly in the RCA.

Frontiers in ImmunologyVol. 17
Sheng Jing Hospital (CN), China Medical University (CN)
Good health and well-being
Kawasaki Disease and Coronary Complications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon